Publications

Export 29 results:
Auteur Title [ Type(Asc)] Année
Filtres: Auteur is Plitman, Eric  [Enlever les filtres]
Journal Article
Chung JKu, Nakajima S, Plitman E, Iwata Y, Uy D, Gerretsen P, Caravaggio F, Chakravarty MM, Graff-Guerrero A.  2016.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.. Am J Geriatr Psychiatry. 24(10):923-39.
Plitman E, Guma E, Lepage M, Near J, Chakravarty MM.  2019.  Using proton magnetic resonance spectroscopic imaging to study glutamatergic alterations in patients with schizophrenia: A systematic review.. Schizophr Res. 210:13-20.
Caravaggio F, Plavén-Sigray P, Matheson GJames, Plitman E, Chakravarty MM, Borg J, Graff-Guerrero A, Cervenka S.  2018.  Trait impulsivity is not related to post-commissural putamen volumes: A replication study in healthy men.. PLoS One. 13(12):e0209584.
Caravaggio F, Plitman E, Chung JKu, Gerretsen P, Kim J, Iwata Y, Chakravarty MM, Remington G, Graff-Guerrero A.  2017.  Trait impulsiveness is related to smaller post-commissural putamen volumes in males but not females.. Eur J Neurosci. 46(7):2253-2264.
Takahashi T, Tsugawa S, Nakajima S, Plitman E, Chakravarty MM, Masuda F, Wada M, Kurose S, Ochi R, Matsushita K et al..  2020.  Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation study.. Schizophr Res.
Plitman E, Chavez S, Nakajima S, Iwata Y, Chung JKu, Caravaggio F, Kim J, Alshehri Y, Chakravarty MM, De Luca V et al..  2018.  Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.. Psychiatry Res Neuroimaging. 273:16-24.
Plitman E, Raihaan P, Chakravarty MM.  2020.  Seeing the bigger picture: multimodal neuroimaging to investigate neuropsychiatric illnesses.. J Psychiatry Neurosci. 45(3):147-149.
Guma E, Plitman E, Chakravarty MM.  2019.  The role of maternal immune activation in altering the neurodevelopmental trajectories of offspring: A translational review of neuroimaging studies with implications for autism spectrum disorder and schizophrenia.. Neurosci Biobehav Rev. 104:141-157.
Caravaggio F, Chung JKu, Plitman E, Boileau I, Gerretsen P, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G et al..  2017.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [(11) C]-raclopride and [(11) C]-(+)-PHNO PET.. Hum Brain Mapp. 38(11):5519-5534.
Wada M, Kurose S, Miyazaki T, Nakajima S, Masuda F, Mimura Y, Nishida H, Ogyu K, Tsugawa S, Mashima Y et al..  2019.  The P300 event-related potential in bipolar disorder: A systematic review and meta-analysis.. J Affect Disord. 256:234-249.
Kim J, Plitman E, Iwata Y, Nakajima S, Mar W, Patel R, Chavez S, Chung JKu, Caravaggio F, Chakravarty MM et al..  2019.  Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders.. Prog Neuropsychopharmacol Biol Psychiatry. :109839.
Chung JKu, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH et al..  2016.  Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment.. J Alzheimers Dis. 49(4):1189-90.
Chung JKu, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH et al..  2015.  Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment.. J Alzheimers Dis. 45(3):907-19.
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, Chavez S, Sawada K, Wada M, Matsui M et al..  2019.  Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.. Neuropsychopharmacology.
Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JKu, Gerretsen P, Kim J, Takeuchi H, Chakravarty MM, Remington G et al..  2017.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.. Schizophr Bull.
Caravaggio F, Gerretsen P, Mar W, Chung JKu, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM et al..  2017.  Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.. Psychoneuroendocrinology. 81:80-87.
Copersino ML, Patel R, Price JS, Visser KFrost, Vitaliano G, Plitman E, Lukas SE, Weiss RD, Janes AC, Chakravarty MM.  2019.  Interactive effects of age and recent substance use on striatal shape morphology at substance use disorder treatment entry.. Drug Alcohol Depend. :107728.
Chung JKu, Plitman E, Nakajima S, Caravaggio F, Iwata Y, Gerretsen P, Kim J, Takeuchi H, Shinagawa S, Patel R et al..  2017.  Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.. J Alzheimers Dis. 58(3):747-762.
Shah P, Plitman E, Iwata Y, Kim J, Nakajima S, Chan N, Brown EE, Caravaggio F, Torres E, Hahn M et al..  2020.  Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity.. J Psychiatr Res. 124:151-158.
Plitman E, Patel R, Chung JKu, Pipitone J, Chavez S, Reyes-Madrigal F, Gómez-Cruz G, León-Ortiz P, Chakravarty MM, de la Fuente-Sandoval C et al..  2016.  Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.. Neuropsychopharmacology. 41(10):2606-13.
Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JKu, Caravaggio F, Iwata Y, Remington G et al..  2014.  Glutamate-mediated excitotoxicity in schizophrenia: a review.. Eur Neuropsychopharmacol. 24(10):1591-605.
Chung JKu, Plitman E, Nakajima S, Caravaggio F, Shinagawa S, Iwata Y, Gerretsen P, Kim J, Takeuchi H, Patel R et al..  2017.  The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report.. J Alzheimers Dis. 60(2):341-347.
Chung JKu, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Takeuchi H, Gerretsen P, Iwata Y, Patel R, Mulsant BH et al..  2016.  Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.. J Alzheimers Dis. 49(3):743-54.
Chung JKu, Plitman E, Nakajima S, Chakravarty MM, Caravaggio F, Gerretsen P, Iwata Y, Graff-Guerrero A.  2016.  Cortical Amyloid β Deposition and Current Depressive Symptoms in Alzheimer Disease and Mild Cognitive Impairment.. J Geriatr Psychiatry Neurol. 29(3):149-59.
Winterburn JL, Voineskos AN, Devenyi GA, Plitman E, de la Fuente-Sandoval C, Bhagwat N, Graff-Guerrero A, Knight J, Chakravarty MM.  2017.  Can we accurately classify schizophrenia patients from healthy controls using magnetic resonance imaging and machine learning? A multi-method and multi-dataset study. Schizophr Res.

Pages